PEGYLATED, EXTENDED INSULINS
    3.
    发明申请
    PEGYLATED, EXTENDED INSULINS 失效
    PEGYLATED,EXTENDED INSULINS

    公开(公告)号:US20110319591A1

    公开(公告)日:2011-12-29

    申请号:US13224538

    申请日:2011-09-02

    IPC分类号: C07K14/62

    CPC分类号: A61K38/28 A61K47/60

    摘要: PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regular insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.

    摘要翻译: 聚乙二醇化的延长胰岛素是胰岛素,其与人胰岛素相比具有从A1,B1,A21和/或B30位置延伸的一个或多个延伸,所述延伸部分包含氨基酸残基(s) ),并且其中通过接头的PEG部分连接到延伸中的一个或多个氨基酸残基。 PEG是聚乙二醇。 这种聚乙二醇化的延长的胰岛素具有比常规胰岛素更高的生物利用度和更长的时间作用特征,并且特别适合于肺部给药,并且可以方便地用于治疗糖尿病。

    Pegylated, Extended Insulins
    8.
    发明申请
    Pegylated, Extended Insulins 审中-公开
    聚乙二醇化,延长胰岛素

    公开(公告)号:US20090306337A1

    公开(公告)日:2009-12-10

    申请号:US12375678

    申请日:2007-07-16

    IPC分类号: C07K14/62

    CPC分类号: A61K38/28 A61K47/60

    摘要: PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regulär insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.

    摘要翻译: 聚乙二醇化的延长胰岛素是胰岛素,其与人胰岛素相比具有从A1,B1,A21和/或B30位置延伸的一个或多个延伸,所述延伸部分包含氨基酸残基(s) ),并且其中通过接头的PEG部分连接到延伸中的一个或多个氨基酸残基。 PEG是聚乙二醇。 这种聚乙二醇化的延长胰岛素具有比调节胰岛素更高的生物利用度和更长的时间作用特征,并且特别适合于肺部给药,并且可以方便地用于治疗糖尿病。

    PEGylated, extended insulins
    10.
    发明授权
    PEGylated, extended insulins 失效
    聚乙二醇化,延长胰岛素

    公开(公告)号:US08710001B2

    公开(公告)日:2014-04-29

    申请号:US13224538

    申请日:2011-09-02

    IPC分类号: A61K38/28

    CPC分类号: A61K38/28 A61K47/60

    摘要: PEGylated, extended insulins are insulins which, compared with human insulin, has one or more extensions extended from the A1, B1, A21 and/or B30 position(s), said extension(s) consist(s) of amino acid residue(s) and wherein a PEG moiety, via a linker, is attached to one or more of the amino acid residues in the extension(s). PEG is polyethyleneglycol. Such PEGylated, extended insulins have higher bioavailability and a longer time-action profile than regular insulin and are in particular suited for pulmonary administration and can, conveniently, be used to treat diabetes.

    摘要翻译: 聚乙二醇化的延长胰岛素是胰岛素,其与人胰岛素相比具有从A1,B1,A21和/或B30位置延伸的一个或多个延伸,所述延伸部分包含氨基酸残基(s) ),并且其中通过接头的PEG部分连接到延伸中的一个或多个氨基酸残基。 PEG是聚乙二醇。 这种聚乙二醇化的延长的胰岛素具有比常规胰岛素更高的生物利用度和更长的时间作用特征,并且特别适合于肺部给药,并且可以方便地用于治疗糖尿病。